

## Metabolic Brain Disease

# THE BILE DUCT LIGATED RAT: A RELEVANT MODEL TO STUDY MUSCLE MASS LOSS IN CIRRHOSIS

--Manuscript Draft--

<b>Manuscript Number:</b>	MEBR-D-16-00160R1
<b>Full Title:</b>	THE BILE DUCT LIGATED RAT: A RELEVANT MODEL TO STUDY MUSCLE MASS LOSS IN CIRRHOSIS
<b>Article Type:</b>	SI: ISHEN
<b>Keywords:</b>	experimental cirrhosis; muscle mass loss; protein synthesis; ammonia; hepatic encephalopathy
<b>Corresponding Author:</b>	Chantal Bêmeur Université de Montréal Montreal, QC CANADA
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Université de Montréal
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Cristina R Bosoi
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Cristina R Bosoi Mariana Oliveira Rafael Ochoa-Sanchez Mélanie Tremblay Gabrie A Ten Have Nicolaas E Deutz Christopher F Rose Chantal Bêmeur
<b>Order of Authors Secondary Information:</b>	
<b>Funding Information:</b>	
<b>Abstract:</b>	Muscle mass loss and hepatic encephalopathy (complex neuropsychiatric disorder) are serious complications of chronic liver disease (cirrhosis) which impact negatively on clinical outcome and quality of life and increase mortality. Liver disease leads to hyperammonemia and ammonia toxicity is believed to play a major role in the pathogenesis of hepatic encephalopathy. However, the effects of ammonia are not brain-specific and therefore may also affect other organs and tissues including muscle. The precise pathophysiological mechanisms underlying muscle wasting in chronic liver disease remains to be elucidated. In the present study, we characterized body composition as well as muscle protein synthesis in cirrhotic rats with hepatic encephalopathy using the 6-week bile duct ligation (BDL) model which recapitulates the main features of cirrhosis. Compared to sham-operated control animals, BDL rats display significant decreased gain in body weight, altered body composition, decreased gastrocnemius muscle mass and circumference as well as altered muscle morphology. Muscle protein synthesis was also significantly reduced in BDL rats compared to control animals. These findings demonstrate that the 6-week BDL experimental rat is a relevant model to study liver disease-induced muscle mass loss.

[Click here to view linked References](#)

1  
2  
3  
4  
5 **THE BILE DUCT LIGATED RAT: A RELEVANT MODEL TO STUDY MUSCLE MASS LOSS IN**  
6 **CIRRHOSIS**  
7

8  
9  
10  
11 Cristina Bosoi<sup>1</sup>, Mariana Oliveira<sup>1</sup>, Rafael Ochoa Sanchez<sup>1</sup>, Mélanie Tremblay<sup>1</sup>, Gabrie A Ten Have<sup>2</sup>, Nicolaas  
12 E Deutz<sup>2</sup>, Christopher F. Rose<sup>1</sup>, Chantal Bemeur<sup>1,3</sup>  
13  
14

15  
16  
17  
18  
19 <sup>1</sup>Hepato-Neuro Laboratory, CRCHUM, Université de Montréal, Montréal, Canada.

20 <sup>2</sup>Center for Translational Research in Aging & Longevity, Department of Health & Kinesiology, Texas A&M  
21 University, Texas, U.S.A.  
22

23 <sup>3</sup>Département de nutrition, Faculté de médecine, Université de Montréal, Montréal, Canada  
24  
25  
26  
27  
28

29 **Running Head :** Experimental cirrhosis and muscle mass loss  
30  
31  
32  
33  
34

35 **Corresponding author :** Chantal Bemeur, Dt.P., Ph.D.  
36  
37 Département de nutrition  
38 Faculté de médecine  
39 Université de Montréal  
40 CP 6128 Succ. Centre-ville  
41 Montréal, Québec, Canada  
42 H3C 3J7  
43 [chantal.bemeur@umontreal.ca](mailto:chantal.bemeur@umontreal.ca)  
44  
45  
46  
47  
48 Phone : 514-343-6111 Ext 15962  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Abstract**

5 Muscle mass loss and hepatic encephalopathy (complex neuropsychiatric disorder) are serious complications of  
6 chronic liver disease (cirrhosis) which impact negatively on clinical outcome and quality of life and increase  
7 mortality. Liver disease leads to hyperammonemia and ammonia toxicity is believed to play a major role in the  
8 pathogenesis of hepatic encephalopathy. However, the effects of ammonia are not brain-specific and therefore may  
9 also affect other organs and tissues including muscle. The precise pathophysiological mechanisms underlying muscle  
10 wasting in chronic liver disease remains to be elucidated. In the present study, we characterized body composition as  
11 well as muscle protein synthesis in cirrhotic rats with hepatic encephalopathy using the 6-week bile duct ligation  
12 (BDL) model which recapitulates the main features of cirrhosis. Compared to sham-operated control animals, BDL  
13 rats display significant decreased gain in body weight, altered body composition, decreased gastrocnemius muscle  
14 mass and circumference as well as altered muscle morphology. Muscle protein synthesis was also significantly  
15 reduced in BDL rats compared to control animals. These findings demonstrate that the 6-week BDL experimental rat  
16 is a relevant model to study liver disease-induced muscle mass loss.  
17  
18  
19  
20  
21  
22  
23  
24

25 **Keywords:** experimental cirrhosis, muscle mass loss, protein synthesis, ammonia, hepatic encephalopathy  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

Loss of muscle mass is the most common and clinically significant complication of chronic liver disease (cirrhosis). It is a major contributor to adverse clinical outcomes (both pre and post liver transplantation), including morbidity and mortality (Merli et al. 2002). In addition, muscle wasting leads to poor quality of life and increased susceptibility to infection (Metter et al. 2002; Pichard et al. 2004; Cosquéric et al. 2006; Millwala et al. 2007; O'Brien and Williams 2008; Montano-Loza et al. 2012; Tandon et al. 2012). It has been suggested that liver disease-induced muscle mass loss results from varying contributions including reduced protein synthesis, increased protein catabolism, and an impaired proliferation and differentiation of skeletal muscle progenitor satellite cells (Dasarathy et al. 2002). However, the precise pathophysiological mechanisms underlying the loss of muscle mass in cirrhosis remains to be elucidated.

Hepatic encephalopathy, another complication of liver disease which greatly impacts on patients' quality of life, is characterized by a constellation of symptoms, including cognitive, psychiatric and motor disturbances (Cash et al. 2010). Although the pathogenesis of hepatic encephalopathy is multifactorial including oxidative stress (Görg et al. 2010; Bosoi et al. 2012), inflammation (Shawcross and Jalan 2005; Shawcross et al. 2011; Montoliu et al. 2009), lactate (Bosoi et al. 2014) and gut microbiota (Bajaj et al. 2008), ammonia is a key player as blood-derived ammonia rises to toxic levels in the brain (Butterworth 2002; Bosoi and Rose 2009). The toxicity of ammonia is a result of its direct effect on pH, membrane potential and metabolism which independently or collectively cause cell dysfunction (Lai and Cooper 1991; Bosoi and Rose 2009). As the effects of ammonia are not brain-specific (Lai and Cooper 1991; Norenberg 2003), it has been shown that elevated concentrations of ammonia can also affect other organs and tissues (Kubota et al. 2004; Jia et al. 2014; Rose 2014).

The 6-week bile duct ligation (BDL) rat, a surgical model involving obstruction of the common bile duct, is a well-established experimental model which recapitulates the main features of cirrhosis including, liver failure, hyperammonemia, secondary biliary cirrhosis, ascites, jaundice, brain edema and hepatic encephalopathy (Butterworth et al. 2009; Bosoi et al. 2011; Bosoi et al. 2012). It has been previously suggested that impaired skeletal muscle protein synthesis is the primary reason for loss of muscle mass in rats with portacaval-systemic shunting (Dasarathy et al. 2011). However, muscle mass in the BDL rat has not been extensively evaluated. The present study aims to characterize body composition as well as muscle protein synthesis in the BDL rats with hepatic encephalopathy.

## Material and Methods

### *Animal model*

Cirrhosis was induced in male Sprague-Dawley rats (200-225 g) (Charles River, St-Constant, QC) by BDL. The latter is created by obstruction of the common bile duct which reproduces the main features of human cirrhosis. Briefly and as previously described, rats were anaesthetized with isoflurane, and the common bile duct ligated and resected under a dissecting microscope. Sham-operated control rats, matched for weight, were similarly anaesthetized; a laparotomy was performed and the bile duct was isolated (Rose et al. 1999; Bosoi et al. 2011; Bosoi

1  
2  
3  
4 et al. 2012). Rats were maintained under controlled conditions (22°C, 12 h: 12 h dark-light cycle) with free access to  
5 their food and water. Two experimental groups were tested; 1) BDL (n=5) and 2) Sham-operated control rats  
6 (SHAM) (n=6). Experiments were conducted following the guidelines of the Canadian Council on Animal Care and  
7 were approved by the Animal Protection Committee of the Centre de recherche du Centre hospitalier de l'Université  
8 de Montréal (CRCHUM).  
9

#### 10 11 12 13 *Body weight and food intake*

14 Body weight was measured every day of the 6 week experimental protocol using an electronic scale. Food  
15 consumption was also monitored every day by the weight of the food.  
16  
17

#### 18 19 20 *Body mass composition*

21 Body composition in terms of lean and fat mass was assessed in conscious rats (full body) by *in vivo* scanning  
22 and magnetic resonance imaging (EchoMRI 100<sup>®</sup> Body Composition Analyzer) 6 weeks after the surgeries,  
23 according to the manufacturer's protocol. The instrument for composition analysis creates contrast between soft  
24 tissues by taking advantage of the differences in relaxation times of the hydrogen proton spins in different  
25 environments. Radio pulses cause protons to spin and emit radio signals which are then received and analysed. The  
26 amplitude, duration, and spatial distribution of these signals are related to properties of the material scanned. The  
27 high contrast between fat, muscle tissue, and free water is further enhanced by application of define composed radio  
28 pulses sequences (Nixon et al. 2010).  
29  
30  
31  
32  
33

#### 34 35 *Gastrocnemius muscle mass, circumference and morphology*

36 At the end of the 6 weeks experimental protocol, rats were sacrificed and the gastrocnemius muscle was  
37 dissected and weighed. Muscle (gastrocnemius) mass and circumference were measured using an electronic scale  
38 and a scaled thread, respectively. Muscle samples were then fixed in 4% paraformaldehyde buffered with phosphate-  
39 buffered saline, decalcified with 10% formic acid, and embedded in paraffin. Longitudinal histology sections were  
40 cut with a microtome, and stained with hematoxylin-eosin. Tissue sections were then visualized using microscope.  
41  
42  
43  
44

#### 45 46 *Protein synthesis*

47 Protein synthesis was quantified as the fractional and absolute protein synthesis rates in the dissected and  
48 homogenized muscle and other organs including the brain (frontal cortex), heart, intestine, kidney and liver, using the  
49 modified phenylalanine tracer pulse method (Zhang et al. 2002; Dasarathy et al. 2011). In brief, rats were given a small  
50 dose (0.5 mg/100 gram body weight) of L-[ring-<sup>2</sup>H<sub>5</sub>]phenylalanine ip at t=0min, L-[1-<sup>13</sup>C]Phenylalanine ip at t=30  
51 min and L-[<sup>15</sup>N]Phenylalanine ip at t=60 min. At t=65min, the rats were killed and blood and tissue collected. The  
52 calculation of the fractional protein synthesis was done by using the enrichment in tissue protein samples of L-[ring-  
53 <sup>2</sup>H<sub>5</sub>]phenylalanine, divided by the average enrichment in plasma (from area under the curve calculation of the curve,  
54 constructed from the three different phenylalanine isotopes). The enrichment of phenylalanine in plasma and tissue  
55 hydrolysates was measured by LC-MS/MS (Engelen et al. 2013; Luiking et al. 2015).  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## *Ammonia*

Ammonia levels were measured in arterial plasma using a commercial kit (Sigma, MO, USA). Ammonia levels were assessed based on the reaction with  $\alpha$ -ketoglutarate and reduced nicotinamide adenine dinucleotide phosphate in the presence of L-glutamate dehydrogenase. Oxidation rate of reduced nicotinamide adenine dinucleotide phosphate was recorded by the absorbance decrease at 340 nm. Ammonia concentration was calculated according to manufacturer's protocol.

## *Statistical analysis*

Data are expressed as mean  $\pm$  standard error of the mean (SEM). Significance of difference was tested with unpaired t test or ANOVA followed by Bonferroni post-test using GraphPad Prism4 (La Jolla, CA, USA). Probability values of  $p < 0.05$  were considered statistically significant.

## **Results**

### *Bile duct ligation-induced cirrhosis leads to decreased gain in body weight*

Body weight was significantly lower in BDL animals compared to SHAM from week 2 to the end of the experimental protocol (week 6) (Figure 1). At 6 weeks, BDL rats weighed  $422.4 \pm 6.15$  g compared to  $509.7 \pm 15.6$  g for sham-operated animals ( $p < 0.001$ ). Over the 6 weeks, daily food intake was similar (non-significant) between the two groups (area under the curve  $1018 \text{ g} \pm 34 \text{ g}$  and  $1078 \pm 21 \text{ g}$  in BDL and SHAM animals, respectively). However, there was a significant difference at week 1 between the two groups ( $13.4 \pm 2.3$  g vs  $17.6 \pm 0.5$  g in BDL and SHAM animals, respectively;  $p < 0.01$ ) (Figure 2)

### *Bile duct ligation-induced cirrhosis provokes altered body composition*

Six weeks after surgery, BDL rats displayed a significant decrease in lean ( $311.2 \pm 12.1$  g vs  $376.5 \pm 11.9$  g;  $t(9)=3.82$ ,  $p < 0.001$ ) and fat ( $33.9 \pm 8.1$  g vs  $89.3 \pm 9.7$  g;  $t(9)=10.15$ ,  $p < 0.001$ ) mass compared with SHAM animals (Figure 3A and 3B), as measured by magnetic resonance.

### *Bile duct ligation-induced cirrhosis leads to decreased gastrocnemius muscle mass and circumference as well as altered muscle morphology*

Compared with control rats, BDL animals had decreased gastrocnemius mass ( $1.92 \pm 0.05$  g vs  $2.85 \pm 0.10$  g;  $t(9)=7.60$ ,  $p < 0.001$ ) and smaller gastrocnemius circumference ( $4.7 \pm 0.2$  cm vs  $5.9 \pm 0.1$  cm;  $t(9)=5.80$ ,  $p < 0.001$ ) (Figure 4A and 4B). A strong correlation was observed between lean and muscle mass in both BDL and SHAM rats ( $r=0.8889$ ;  $p=0.0003$ ) (Figure 4C). Gastrocnemius muscle morphology was analyzed by histological analysis of muscular tissues in SHAM and BDL animals at the end of the 6 week experimental protocol. Hematoxylin-eosin staining revealed disorganized fibres in BDL muscles (Figure 4D).

### *Bile duct ligation-induced cirrhosis reduces muscle protein synthesis*

1  
2  
3  
4 Muscle protein synthesis, 6 weeks after surgery, was significantly reduced in BDL rats compared to SHAM  
5 animals ( $0.32 \pm 0.02$  %/h and  $0.17 \pm 0.07$  %/h, respectively;  $t(10)=1.81$ ,  $p<0.05$ ), as evidenced by decreased  
6 fractional synthesis rate, whereas protein synthesis in other organs including the brain, heart, intestine, kidney, liver  
7 and lung was unaltered (Table 1).  
8  
9

#### 10 11 12 13 *Bile duct ligation-induced cirrhosis increases ammonia levels*

14 Arterial ammonia significantly increased in BDL rats ( $129.0 \pm 14.8$   $\mu\text{M}$  vs  $42.1 \pm 8.2$   $\mu\text{M}$  respectively;  
15  $t(9)=5.38$ ,  $p<0.001$ ) (Figure 5).  
16  
17  
18

#### 19 **Discussion**

20 Results of the present study demonstrate that BDL (6 week model) is associated with significant alteration in  
21 body composition as evidenced by decreased lean and fat mass, reduced gastrocnemius muscle mass and  
22 circumference as well as altered muscle morphology. The strong correlation observed between gastrocnemius mass  
23 (weight) and overall lean mass (assessed by MRI) indicates that gastrocnemius is representative of muscle body  
24 composition. Interestingly, our results also indicate a significant decrease in fat mass in BDL compared to SHAM  
25 rats. This reduction could be a result of fat mass been used as an energy source in order to maintain muscle mass  
26 during liver disease. The mechanisms responsible for fat mass decrease in experimental cirrhosis remain to be  
27 elucidated.  
28  
29  
30  
31  
32  
33

34 We found altered muscle morphology in BDL compared to SHAM rats which is most likely due to collapse of a  
35 smaller muscle. The mechanisms responsible for this alteration remain elusive. In addition to significant changes in  
36 muscle morphology, our results also revealed muscle protein synthesis is significantly decreased in BDL animals  
37 compared to SHAM. Impaired muscle protein synthesis may represent a major cause for muscle mass loss in  
38 experimental cirrhosis. Interestingly, alteration in protein synthesis was specific to the muscle as the protein  
39 synthesis rate was unchanged in the brain, heart, intestine, kidney, liver and lung between the two experimental  
40 groups. We speculate that ammonia may exert a deleterious effect on the muscle and contribute to its dysfunction by  
41 altering protein synthesis. This is supported with studies demonstrating hyperammonemia induced by portacaval-  
42 systemic shunting is associated with reduced muscle mass synthesis (Dasarathy et al. 2011; Davuluri et al. 2016).  
43  
44  
45  
46  
47  
48  
49

50 Our study also indicate that BDL-induced cirrhosis leads to decreased gain in body weight compared to sham-  
51 operated animals, whereas food intake remains similar from week 2 to week 6. The statistical difference in food  
52 intake observed at week 1 (a consistent observation found with our extensive experience with this model) (Rose et al.  
53 1999; Bosoi et al. 2011; Bosoi et al. 2012) may be explained by the invasive nature of the BDL surgery along with  
54 the recovery phase required for such a surgical procedure. This suggests that nutritional problems occur during the  
55 setting of cirrhosis which may include, among other mechanisms, metabolic alterations, malabsorption of nutrients,  
56 increased intestinal protein losses, disturbance of substrate utilization and increased energy expenditure (Bémeur et  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 al. 2010). Specifically, hypermetabolic state and increased energy-protein expenditure and requirements may occur  
5 in chronic liver disease. Indeed, the hyperdynamic circulation in cirrhosis leads to systemic vasodilation and an  
6 expanded intravascular blood volume which consequently leads to a greater use of macro- and micro-nutrients; hence  
7 causing a high energy expenditure and demand. Also, the inflammatory state associated with the inability of the liver  
8 to adequately clear activated proinflammatory mediators may result in hypermetabolism (Tilg et al. 1992; von Baehr  
9 et al. 2000). Regarding malabsorption, the cirrhotic liver may inadequately synthesize proteins and has diminished  
10 storage capacity and an impaired enterohepatic cycle. In addition, portal hypertensive enteropathy may lead to  
11 impaired absorption of essential nutrients. Moreover, pancreatic insufficiency, cholestasis, and drug-related diarrhea  
12 may all contribute to malabsorption in liver disease. Loss of proteins may result from complications of cirrhosis or  
13 from iatrogenic interventions including the use of diuretics for the treatment of ascites and fluid retention as well as  
14 the use of lactulose for the treatment of hepatic encephalopathy. Blood loss from oesophageal and gastric varices and  
15 from the intestinal lumen due to ulcers or portal enteropathy may also lead to increased protein loss in cirrhosis.  
16  
17  
18  
19  
20  
21  
22  
23

24 Several factors have been implicated in the pathogenesis of hepatic encephalopathy, including ammonia (Cooper  
25 and Plum 1987; Felipo and Butterworth 2002), oxidative stress (Görg et al. 2010; Bosoi et al. 2012), inflammation  
26 (Shawcross and Jalan 2005; Montoliu et al. 2009), lactate (Bosoi et al. 2014) and gut microbiota (Bajaj et al. 2008).  
27 Ammonia is considered the major factor in the pathogenesis of hepatic encephalopathy as hyperammonemia leads to  
28 toxic levels of ammonia in the brain (Cooper and Plum 1987; Felipo and Butterworth 2002). During liver disease,  
29 extra-hepatic ammonia metabolism is altered and, with muscle expressing an ammonia-lowering enzyme, glutamine  
30 synthetase, muscle plays a critical compensatory role in attenuating hyperammonemia. However muscle wasting can  
31 exasperate the degree of hyperammonemia and may play a pivotal role in the risk of developing hepatic  
32 encephalopathy (Qiu et al. 2012; Montano-Loza et al. 2014; Rombouts et al., 2016). The underlying causes of  
33 muscle wasting in liver disease remain undetermined. However, paradoxically, it has been demonstrated that high  
34 ammonia concentrations leads to muscle dysfunction and reduction in protein synthesis (Qiu et al. 2012; Qiu et al.  
35 2013). An understanding of ammonia and its removing vs pathophysiological pathways is totally unclear and  
36 remains to be thoroughly investigated.  
37  
38  
39  
40  
41  
42  
43  
44

45 We conclude that the 6-week BDL experimental model is an excellent model to study liver disease-induced  
46 muscle mass loss. Demonstration of similar alterations in human cirrhosis will potentially enhance our understanding  
47 of the mechanisms of muscle mass loss in liver disease. Importantly, understanding these mechanisms will allow the  
48 identification of therapeutic targets to prevent muscle mass loss and ameliorate the quality of life and the prognostic  
49 of patient suffering from liver disease.  
50  
51  
52  
53

#### 54 **Acknowledgments**

55 We thank the Metabolic Phenotyping core facility of CRCHUM for EchoMRI.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## References

- Bajaj JS, Saeian K, Christensen KM, et al (2008) Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy. *Am J Gastroenterol* 103:1707–1715. doi: 10.1111/j.1572-0241.2008.01861.x
- Bémeur C, Desjardins P, Butterworth RF (2010) Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. *J Nutr Metab* 2010:489823. doi: 10.1155/2010/489823
- Bosoi CR, Parent-Robitaille C, Anderson K, et al (2011) AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile-duct ligated rats. *Hepatology* 53:1995–2002. doi: 10.1002/hep.24273
- Bosoi CR, Rose CF (2009) Identifying the direct effects of ammonia on the brain. *Metab Brain Dis* 24:95–102. doi: 10.1007/s11011-008-9112-7
- Bosoi CR, Yang X, Huynh J, et al (2012) Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure. *Free Radic Biol Med* 52:1228–1235. doi: 10.1016/j.freeradbiomed.2012.01.006
- Bosoi CR, Zwingmann C, Marin H, et al (2014) Increased brain lactate is central to the development of brain edema in rats with chronic liver disease. *J Hepatol* 60:554–560. doi: 10.1016/j.jhep.2013.10.011
- Butterworth RF (2002) Pathophysiology of hepatic encephalopathy: a new look at ammonia. *Metab Brain Dis* 17:221–227.
- Cash WJ, McConville P, McDermott E, et al (2010) Current concepts in the assessment and treatment of hepatic encephalopathy. *QJM : monthly journal of the Association of Physicians* 103:9–16. doi: 10.1093/qjmed/hcp152
- Cooper AJ, Plum F (1987) Biochemistry and physiology of brain ammonia. *Physiol Rev* 67:440–519.
- Cosquéric G, Sebag A, Ducolombier C, et al (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. *Br J Nutr* 96:895–901.
- Dasarathy S, McCullough AJ, Muc S, et al (2011) Sarcopenia associated with portosystemic shunting is reversed by follistatin. *J Hepatol* 54:915–921. doi: 10.1016/j.jhep.2010.08.032
- Dasarathy S, Mullen KD, Conjeevaram HS, et al (2002) Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. *Dig Dis Sci* 47:1936–1942.
- Davuluri G, Krokowski D, Guan B-J, et al (2016) Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis. *J Hepatol*. doi: 10.1016/j.jhep.2016.06.004
- Engelen MPKJ, Com G, Wolfe RR, Deutz NEP (2013) Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis. *J Cyst Fibros* 12:445–453. doi: 10.1016/j.jcf.2012.12.011
- Felipo V, Butterworth RF (2002) Neurobiology of ammonia. *Prog Neurobiol* 67:259–279. doi: 10.1016/S0301-0082(02)00019-9
- Görg B, Qvartskhava N, Bidmon H-J, et al (2010) Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. *Hepatology* 52:256–265. doi: 10.1002/hep.23656
- Jia B, Yu Z-J, Duan Z-F, et al (2014) Hyperammonaemia induces hepatic injury with alteration of gene expression profiles. *Liver Int* 34:748–758. doi: 10.1111/liv.12365

- 1  
2  
3  
4 Kubota Y, Kato K, Dairaku N, et al (2004) Contribution of glutamine synthetase to ammonia-induced apoptosis in  
5 gastric mucosal cells. *Digestion* 69:140–148. doi: 10.1159/000078152  
6  
7 Lai JC, Cooper AJ (1991) Neurotoxicity of ammonia and fatty acids: differential inhibition of mitochondrial  
8 dehydrogenases by ammonia and fatty acyl coenzyme A derivatives. *Neurochem Res* 16:795–803.  
9  
10 Luiking YC, Poeze M, Deutz NE (2015) Arginine infusion in patients with septic shock increases nitric oxide  
11 production without haemodynamic instability. *Clin Sci* 128:57–67. doi: 10.1042/CS20140343  
12  
13 Merli M, Nicolini G, Angeloni S, Riggio O (2002) Malnutrition is a risk factor in cirrhotic patients undergoing  
14 surgery. *Nutrition* 18:978–986.  
15  
16 Metter EJ, Talbot LA, Schrager M, Conwit R (2002) Skeletal muscle strength as a predictor of all-cause mortality in  
17 healthy men. *J Gerontol A Biol Sci Med Sci* 57:B359-365.  
18  
19 Millwala F, Nguyen GC, Thuluvath PJ (2007) Outcomes of patients with cirrhosis undergoing non-hepatic surgery:  
20 risk assessment and management. *World J Gastroenterol* 13:4056–4063.  
21  
22 Montano-Loza AJ, Duarte-Rojo A, Rose CF (2014) Sarcopenia and myosteatosis increase the risk of hepatic  
23 encephalopathy in cirrhotic patients. In: *Hepatology*. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN  
24 07030-5774, NJ USA, p 384A–385A  
25  
26 Montano-Loza AJ, Meza-Junco J, Prado CMM, et al (2012) Muscle wasting is associated with mortality in patients  
27 with cirrhosis. *Clin Gastroenterol Hepatol* 10:166–173. doi: 10.1016/j.cgh.2011.08.028  
28  
29 Montoliu C, Piedrafita B, Serra MA, et al (2009) IL-6 and IL-18 in blood may discriminate cirrhotic patients with  
30 and without minimal hepatic encephalopathy. *J Clin Gastroenterol* 43:272–279. doi:  
31 10.1097/MCG.0b013e31815e7f58  
32  
33 Nixon J, Zhang M, Wang C, et al (2010) Evaluation of a quantitative magnetic resonance imaging system for whole  
34 body composition analysis in rodents. *Obesity (Silver Spring)* 18:1652–1659. doi: 10.1038/oby.2009.471  
35  
36 Norenberg MD (2003) Oxidative and nitrosative stress in ammonia neurotoxicity. *Hepatology* 37:245–8. doi:  
37 10.1053/jhep.2003.50087  
38  
39 O'Brien A, Williams R (2008) Nutrition in end-stage liver disease: principles and practice. *Gastroenterology*  
40 134:1729–1740. doi: 10.1053/j.gastro.2008.02.001  
41  
42 Pichard C, Kyle UG, Morabia A, et al (2004) Nutritional assessment: lean body mass depletion at hospital admission  
43 is associated with an increased length of stay. *Am J Clin Nutr* 79:613–618.  
44  
45 Qiu J, Thapaliya S, Runkana A, et al (2013) Hyperammonemia in cirrhosis induces transcriptional regulation of  
46 myostatin by an NF-κB-mediated mechanism. *Proc Natl Acad Sci USA* 110:18162–18167. doi:  
47 10.1073/pnas.1317049110  
48  
49 Qiu J, Tsien C, Thapalaya S, et al (2012) Hyperammonemia-mediated autophagy in skeletal muscle contributes to  
50 sarcopenia of cirrhosis. *Am J Physiol Endocrinol Metab* 303:E983-993. doi: 10.1152/ajpendo.00183.2012  
51  
52 Rombouts K, Bémeur C, Rose CF. Targeting the muscle for the treatment and prevention of hepatic encephalopathy.  
53 *J Hepatol*. doi:10.1016/j.jhep.2016.08.014.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Rose C, Butterworth RF, Zayed J, et al (1999) Manganese deposition in basal ganglia structures results from both  
5 portal-systemic shunting and liver dysfunction. *Gastroenterology* 117:640–644. doi: 10.1016/S0016-  
6 5085(99)70457-9  
7  
8 Rose CF (2014) Ammonia: more than a neurotoxin? *Liver Int* 34:649–651. doi: 10.1111/liv.12518  
9  
10 Shawcross DL, Sharifi Y, Canavan JB, et al (2011) Infection and systemic inflammation, not ammonia, are  
11 associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. *J hepatol* 54:640–649.  
12  
13 Shawcross D, Jalan R (2005) The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and  
14 inflammation. *Cell Mol Life Sci* 62:2295–304. doi: 10.1007/s00018-005-5089-0  
15  
16 Tandon P, Ney M, Irwin I, et al (2012) Severe muscle depletion in patients on the liver transplant wait list: its  
17 prevalence and independent prognostic value. *Liver Transpl* 18:1209–1216. doi: 10.1002/lt.23495  
18  
19 Tilg H, Wilmer A, Vogel W, et al (1992) Serum levels of cytokines in chronic liver diseases. *Gastroenterology*  
20 103:264–274.  
21  
22 von Baehr V, Döcke WD, Plauth M, et al (2000) Mechanisms of endotoxin tolerance in patients with alcoholic liver  
23 cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor  
24 receptors as well as effector cell desensitisation. *Gut* 47:281–287.  
25  
26 Zhang X-J, Chinkes DL, Wolfe RR (2002) Measurement of muscle protein fractional synthesis and breakdown rates  
27 from a pulse tracer injection. *Am J Physiol Endocrinol Metab* 283:E753-764. doi:  
28 10.1152/ajpendo.00053.2002  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Figures Legends**

5  
6 **Table 1 Protein synthesis of organs in rats with bile-duct ligation (BDL) compared to**  
7 **sham-operated controls.**

8  
9 \* $p < 0.05$ , significantly different from SHAM.  
10

11  
12  
13 **Fig 1 Growth curve of rats with bile-duct ligation (BDL) compared to sham-operated**  
14 **controls.**

15  
16  
17 Mean of daily weights were averaged and expressed as weekly weight. The two way ANOVA  
18 indicated an effect of time/week ( $F_{5, 54} = 231.94, p < 0.001$ ), an effect of surgery ( $F_{1, 54} = 85.93,$   
19  $p < 0.001$ ) and interaction ( $F_{1, 54} = 2.47, p = 0.04$ ). \*\* $p < 0.01$ , \*\*\*  $p < 0.001$ , significantly different  
20 from SHAM.  
21  
22  
23  
24  
25

26 **Fig 2 Food intake of rats with bile-duct ligation (BDL) compared to sham-operated**  
27 **controls.**

28  
29 Mean of daily food intake were averaged and expressed as weekly intake. The two way  
30 ANOVA indicated an effect of time/week ( $F_{5, 54} = 98.21, p < 0.001$ ) and an effect of surgery ( $F_{1, 54} = 11.22,$   
31  $p < 0.001$ ), with no interaction ( $F_{1, 54} = 1.47, p = 0.21$ ). \*\*  $p < 0.01$ , significantly different  
32 from SHAM.  
33  
34  
35  
36  
37  
38

39 **Fig 3 Lean mass (A) and fat mass (B) in rats with bile-duct ligation (BDL) compared to**  
40 **sham-operated controls.**


41  
42 \*\*\*  $p < 0.001$ , significantly different from SHAM.  
43  
44  
45


46 **Fig 4 Gastrocnemius muscle mass (A), muscle circumference (B), correlation between lean**  
47 **mass and gastrocnemius mass (C) and muscle histology of rats with bile-duct ligation (BDL)**  
48 **compared to sham-operated controls.**


49  
50  
51 \*\*\*  $p < 0.001$ , significantly different from SHAM. Bar= 10  $\mu\text{m}$   
52  
53  
54

55 **Fig 5 Serum ammonia in rats with bile-duct ligation (BDL) compared to sham-operated**  
56 **controls.**

57  
58  
59 \*  $p < 0.05$ , significantly different from SHAM.  
60  
61  
62  
63  
64  
65






















SHAM



BDL



	SHAM	BDL
Frontal Cortex (%/hour)	0,63 ± 0,25	0,56 ± 0,07
Heart (%/hour)	0,68 ± 0,31	0,64 ± 0,14
Intestine (%/hour)	4,46 ± 1,21	3,42 ± 1,34
Kidney (%/hour)	2,34 ± 0,92	1,73 ± 0,29
Liver (%/hour)	3,45 ± 1,29	2,95 ± 0,67
Lung (%/hour)	1,08 ± 0,39	1,25 ± 0,31
Muscle (%/hour)	0,32 ± 0,19	0,17 ± 0,07 *